ZYDUSLIFENSEZydus Lifesciences LimitedMediumNeutral
Announced Tue, 19 May · 14:15 IST

Zydus Lifesciences Limited has informed the Exchange regarding Change in Director(s) of the company.

Management Changes View source PDF

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.9%1-day move
₹992.00
prior close
₹1028.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.7+1.9+1.0+1.2+4.9+4.5+4.7+8.0+8.6+9.1+10.6+8.1+15.8
Up moveDown movePending
AI summary

Zydus Lifesciences announced two board changes at its May 19, 2026 meeting. First, it re-appointed Dr. Sharvil P. Patel as Managing Director for another 5-year term starting April 1, 2027, subject to shareholder approval at the AGM. Dr. Sharvil is the son of Chairman Pankaj R. Patel and has been leading the company, which is known for its pharma products like Sugar Free and Glucon D. Second, it appointed Mr. Kulin S. Lalbhai as an Additional and Independent Director for 5 years effective May 19, 2026. Mr. Lalbhai brings digital and consumer business expertise from his current role as Whole Time Director at Arvind Limited. Both appointments require shareholder approval.

Likely market impact

The re-appointment of Dr. Sharvil Patel provides continuity in leadership and is positive for stability. The addition of Mr. Kulin Lalbhai as an Independent Director strengthens board independence and brings fresh external expertise in digital and consumer businesses.